Dr. Kosari on Antitumor Immunity in Small Cell Lung Cancer

Video

Farhad Kosari, PhD, assistant professor of Biochemistry and Molecular Biology, discusses anti-tumor immunity as a key determinant for small-cell lung cancer (SCLC) survivorship.

Farhad Kosari, PhD, assistant professor of Biochemistry and Molecular Biology, discusses antitumor immunity as a key determinant for small cell lung cancer (SCLC) survivorship.

When comparing factors that contribute to long-term survivorship in SCLC, Kosari found a group of patients who survived 4 years, and compared their tumors with patients who had the expected survival of 2 years. The gene expression data showed that the differences were based on tumor immunity.

There is potential for immunotherapy to be applied to patients if the immune system can be activated, Kosari explains. Patients who have autoimmune disease generally have long-term survival and this study gives more details as to the different components of the immune system that need to be activated to achieve longer survival.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS